30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Product / Company Performance

Integra LifeSciences Reports 3Q16 Revenue -

ORTHOWORLD estimates Integra LifeSciences' (IART) 3Q16 orthopaedic revenue at US $27.7MM, +15.4% from 3Q15 as-reported.

ORTHOWORLD estimates 3Q16 segment sales and growth on an as-reported basis, as follows.

  • Joint Reconstruction Extremities $5.7MM, +16.6%
  • Trauma $22.0MM, +15.1%


  • Growth primarily driven by contributions from Salto acquisition; excluding the acquisition, extremity hardware sales “up slightly” and led by Titan shoulder recon
  • Salto ankle and Futura toe revenue ~$3.2MM in 3Q16 and ~$10.5MM YTD
  • Expecting early 2017 decisions on 2H17 ex-U.S. rights to Salto (recall that IART’s acquisition of Tornier’s Salto ankle and Futura toe products included an option to purchase ex-U.S. rights to certain products) Preparing for global full market launch of Cadence ankle and expanding surgeon education for Cadence and Salto systems
  • Received FDA 510(k) clearance within quarter for Titan Reverse Shoulder
  • Announced successful completion of initial procedures using the Cadence Total Ankle in Europe

Sources: Integra LifeSciences Corporation; ORTHOWORLD Inc.


This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.